(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Embracing Practical Living and Ecological Protection - 2Vote in favor of your Favored kind of footwear
- 321 Incredibly Entertaining Contemplations To Observe Consistently
- 4Step by step instructions to Advance the Eco-friendliness of Your Kona SUV
- 5The most effective method to Guarantee Thorough Inclusion in Senior Protection.
- Vote in favor of Your Number one tabletop game
- Best Augmented Experience Ride: Which One Feels Generally Genuine?
- 6 Solid Vehicle Fix Administrations to Keep Your Vehicle in Prime Condition
- The most effective method to Arrange a Higher Medical caretaker Pay During Your Next New employee screening
- The 10 Most Famous Style Minutes on Honorary pathway
- A definitive Manual for Picking Electric Vehicle: Decision in favor of Your Number one
- Family-Accommodating Snow Sports Experiences
- Influencers are selling a delusional fantasy of being postpartum. Why is it so easy to believe?
- Family-Accommodating Snow Sports Experiences
